PsyMed Ventures provides capital and support to the best and most innovative companies that align healing, responsibility, and profitability.

We’re in a mental health crisis. 2 in 5 Americans live with a mental illness. Current approaches to deal with mental health focus on addressing symptoms and not root causes. It doesn't need to be this way.

PsyMed Ventures invests in new paradigms in addressing mental health: psychedelic medicine, neurotech, precision psychiatry, among other frontier technologies. We believe these healing modalities are 10X better than the current standard of care.

We’re uniquely positioned to identify and source companies given our involvement as podcast hosts, entrepreneurs, and the earliest investors in psychedelics. And we're donating 4.19% of our profit to psychedelic non-profits and indigenous communities (4/19 is Bicycle Day!) since we are standing on the shoulders of giants.

We recently launched the PsyMed fund and we're prioritizing LPs currently in the fund for co-investment opportunities. At the same time, we'll aim to carve out small allocations for syndicate members as many of them are advocates and/or are active participants in the space.

If you're interested to learn more about PsyMed Ventures Fund I, please get in touch (hi@psymed.ventures).

PsyMed Ventures is at the center of the mental health startup ecosystem. Matias and Greg host Business Trip, a podcast about psychedelic and mental health startups. The podcast is a great platform to meet the best and brightest in the field. Dina is one of the most active angel investors in psychedelics and mental health with 20+ investments in the space.

Psychedelic investment must be handled responsibly given the power of these medicines and the history of psychedelics. The three of us are deeply committed to bringing psychedelic-assisted therapy to market safely and quickly, while staying true to the spirit of the medicine.